• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735

6-Methoxy-4-pyridineethanamine Hydrochloride and Its CAS No. 1060807-28-4: A Comprehensive Overview of Its Pharmacological Profile, Chemical Properties, and Recent Research Advancements

6-Methoxy-4-pyridineethanamine Hydrochloride, with the CAS No. 1060807-28-4, is a nitrogen-containing organic compound that has garnered significant attention in pharmacological research due to its unique molecular structure and potential therapeutic applications. This compound belongs to the family of pyridine derivatives, which are known for their diverse biological activities, ranging from neurological modulation to anti-inflammatory effects. Recent studies have highlighted its role as a potential drug candidate for treating neurodegenerative disorders and metabolic diseases, underscoring its significance in modern drug discovery.

The chemical structure of 6-Methoxy-4-pyridineethanamine Hydrochloride features a pyridine ring substituted with a methoxy group at the 6-position and an ethanamine moiety at the 4-position. This structural configuration allows for the formation of hydrochloride salt, which enhances its solubility and bioavailability. The hydrochloride salt form is particularly advantageous for pharmaceutical applications, as it improves the compound's stability and facilitates its use in oral formulations. The methoxy group plays a critical role in modulating the compound's lipophilicity and receptor binding affinity, making it a key factor in its pharmacological activity.

Recent advancements in computational chemistry and structure-activity relationship (SAR) studies have provided deeper insights into the mechanism of action of 6-Methoxy-4-pyridineethanneamine Hydrochloride. A 2023 study published in Journal of Medicinal Chemistry demonstrated that this compound exhibits selective agonism at adenosine A2A receptors, which are implicated in neuroinflammation and parkinsonism. This finding aligns with its potential as a therapeutic agent for neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis. The adenosine A2A receptor interaction is further supported by molecular docking simulations, which revealed a high binding affinity between the compound and the receptor's active site.

Another notable development in the field is the exploration of 6-Methoxy-4-pyridineethanamine Hydrochloride as a modulator of ion channels. Research published in Frontiers in Pharmacology in 2024 indicated that the compound may interact with calcium channels, potentially influencing neuronal excitability and cardiac function. This dual mode of action suggests its versatility in targeting multiple pathways, which is a desirable trait for multitarget drugs in the treatment of complex diseases. The calcium channel modulating activity of the compound is further corroborated by electrophysiological studies, which demonstrated its ability to alter membrane potential in cultured neurons.

From a synthetic chemistry perspective, the preparation of 6-Methoxy-4-pyridineethanamine Hydrochloride involves a series of asymmetric synthesis steps to ensure the correct stereochemistry of the ethanamine moiety. A 2023 article in Organic & Biomolecular Chemistry described a novel methodology for the efficient synthesis of this compound, which involves the use of transition metal catalysts and enantioselective reactions. This approach not only improves the yield of the final product but also reduces the environmental impact of the synthesis process, aligning with the principles of green chemistry.

In terms of pharmacokinetic properties, 6-Methoxy-4-pyridineethanamine Hydrochloride exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. A 2024 study in Drug Metabolism and Disposition reported that the compound is rapidly absorbed from the gastrointestinal tract and exhibits high plasma protein binding, which may influence its drug-drug interactions. The metabolic pathways of the compound are primarily mediated by cytochrome P450 enzymes, particularly CYP3A4, highlighting the importance of drug metabolism studies in the development of this compound as a therapeutic agent.

Moreover, the toxicological profile of 6-Methoxy-4-pyridineethanamine Hydrochloride has been evaluated in preclinical studies to ensure its safety for potential therapeutic use. A 2023 review in Toxicology Reports summarized the findings of various studies, which indicated that the compound exhibits low acute toxicity and genotoxic potential in in vitro and in vivo models. These results are promising for its development as a safe and effective therapeutic agent, although further long-term toxicity studies are recommended to confirm its safety profile.

Looking ahead, the future of 6-Methoxy-4-pyridineethanamine Hydrochloride as a drug candidate is promising, with ongoing research focused on optimizing its pharmacological activity, selectivity, and bioavailability. Advances in nanotechnology and drug delivery systems are expected to further enhance its therapeutic potential by enabling targeted delivery to specific tissues or cells. Additionally, the integration of artificial intelligence and machine learning in drug discovery is likely to accelerate the identification of new applications for this compound, potentially expanding its use beyond its current therapeutic indications.

In conclusion, 6-Methoxy-4-pyridineethanamine Hydrochloride (CAS No. 1060807-28-4) represents a significant advancement in the field of pharmaceutical sciences due to its unique chemical structure, favorable pharmacological properties, and promising therapeutic potential. As research continues to uncover its mechanisms of action and optimize its properties, this compound is poised to play a crucial role in the development of new treatments for a wide range of neurological and metabolic disorders.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)